Related Experiment Video
Updated: Jul 10, 2026
07:47
Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma
Published on: August 31, 2022
Fluoromethylcholine PET in recurrent multifocal hepatoma
N P Lenzo1, J Anderson, A Campbell
1WA PET/Cyclotron Service, Sir Charles Gairdner Hospital, Perth, Australia. nlenzo@mac.com
Australasian Radiology
|January 3, 2008
Summary
New imaging tracer, fluoromethylcholine (FCH) PET, effectively visualized recurrent multifocal hepatoma. This shows promise for patients with poor FDG-avid liver tumors where standard PET scans are less effective.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiology
Background:
- Hepatocellular carcinoma (HCC) evaluation using F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) shows variable efficacy.
- There is a need for improved imaging tracers for recurrent or poorly FDG-avid liver tumors.
Observation:
- A case study involving a patient with a history of hepatocellular carcinoma and a poorly FDG-avid hepatic tumor is presented.
- The patient exhibited recurrent multifocal hepatoma.
Findings:
- Fluoromethylcholine (FCH) PET imaging successfully visualized the recurrent multifocal hepatoma.
- The FCH PET findings demonstrated excellent correlation with computed tomography (CT) hepatic angiography results.
Implications:
- Fluoromethylcholine (FCH) PET may offer a valuable alternative or complementary imaging modality for detecting recurrent hepatocellular carcinoma, especially in cases with low FDG avidity.
- This highlights the potential of novel PET tracers in improving oncologic imaging and patient management for liver cancer.
